Biogen Idec to Acquire Fumapharm AG; Consolidates Ownership of Oral Compound BG-12 Being Studied for Multiple Sclerosis.
Linked as:
Extract
Biogen Idec to Acquire Fumapharm AG; Consolidates Ownership of Oral Compound BG-12 Being Studied for Multiple Sclerosis.
CAMBRIDGE, Mass. and LUCERNE, Switzerland -- Biogen Idec (NASDAQ: BIIB) and Fumapharm AG, a privately held pharmaceutical company, today announced that they have signed a definitive agreement for the acquisition of Fumapharm by Biogen Idec.
Fumapharm AG, founded i...See the full content of this document
Sponsored links
